Synergy Pharmaceuticals Inc., (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is engaged in the field of human therapeutics. The Company�s products include plecanatide, SP-333 and FV-100. Plecanatide is a guanylate cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is also developing SP-333, a second generation GC-C receptor agonist for the treatment of inflammatory bowel diseases, such as ulcerative colitis (UC). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for ulcerative colitis (UC), an inflammatory bowel disease. The Company�s subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.